{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:02:05Z","timestamp":1777406525250,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,4,16]],"date-time":"2009-04-16T00:00:00Z","timestamp":1239840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s00280-009-0992-y","type":"journal-article","created":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T08:01:37Z","timestamp":1239782497000},"page":"1221-1233","source":"Crossref","is-referenced-by-count":28,"title":["Antiangiogenic and antiproliferative effects of substituted-1,3,4-oxadiazole derivatives is mediated by down regulation of VEGF and inhibition of translocation of HIF-1\u03b1 in Ehrlich ascites tumor cells"],"prefix":"10.1007","volume":"64","author":[{"given":"Akhilesh","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saritha S.","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin Raj","family":"Mysore Nagaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. L.","family":"Gaonkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharathi P.","family":"Salimath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. M. Lokanatha","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,4,16]]},"reference":[{"issue":"7","key":"992_CR1","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1134\/S0006297908070031","volume":"73","author":"AF Karamysheva","year":"2008","unstructured":"Karamysheva AF (2008) Mechanism of angiogenesis. Biochemistry (Mosc) 73(7):751\u2013762","journal-title":"Biochemistry (Mosc)"},{"key":"992_CR2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182\u20131186","journal-title":"N Engl J Med"},{"key":"992_CR3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","volume":"86","author":"D Hanahan","year":"1996","unstructured":"Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353\u2013364","journal-title":"Cell"},{"key":"992_CR4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","volume":"1","author":"J Folkman","year":"1995","unstructured":"Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27\u201331","journal-title":"Nat Med"},{"key":"992_CR5","first-page":"39","volume":"9","author":"S Folkman","year":"1997","unstructured":"Folkman S, Chesney M (1997) Grief Vancouver conference review. AIDS Care 9:39\u201343","journal-title":"AIDS Care"},{"key":"992_CR6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.seminoncol.2007.09.009","volume":"34","author":"GH Mahabeleshwar","year":"2007","unstructured":"Mahabeleshwar GH, Byzova TV (2007) Angiogenesis in melanoma. Semin Oncol 34:555\u2013565","journal-title":"Semin Oncol"},{"issue":"8","key":"992_CR7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2174\/156800907783220462","volume":"7","author":"PP Goh","year":"2007","unstructured":"Goh PP, Sze DM, Roufogalis BD (2007) Molecular and cellular regulators of cancer angiogenesis. Curr Cancer Drug Targets 7(8):743\u2013758","journal-title":"Curr Cancer Drug Targets"},{"issue":"5","key":"992_CR8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000151706","volume":"75","author":"YT Ding","year":"2008","unstructured":"Ding YT, Kumar S, Yu DC (2008) The role of endothelial progenitor cells in tumor vasculogenesis. Pathobiology 75(5):265\u2013273","journal-title":"Pathobiology"},{"key":"992_CR9","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI6889","volume":"103","author":"JM Inser","year":"1999","unstructured":"Inser JM, Asahara T (1999) Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Investig 103:1231\u20131236","journal-title":"J Clin Investig"},{"key":"992_CR10","doi-asserted-by":"crossref","unstructured":"Bao P, Kodra A, Tomic-Canic M, Golinko MS, Ehrlich HP, Brem H (2008) The role of vascular endothelial growth factor in wound healing. J Surg Res. doi: 10.1016\/j.jss.2008.04.023","DOI":"10.1016\/j.jss.2008.04.023"},{"key":"992_CR11","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1210\/mend-5-12-1806","volume":"5","author":"KA Houck","year":"1991","unstructured":"Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806\u20131814","journal-title":"Mol Endocrinol"},{"key":"992_CR12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1200\/JCO.1995.13.3.765","volume":"13","author":"G Gasparini","year":"1995","unstructured":"Gasparini G, Harris AL (1995) Clinical implications of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 13:765\u2013782","journal-title":"J Clin Oncol"},{"key":"992_CR13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/10799900050023933","volume":"20","author":"B Stoelcker","year":"2000","unstructured":"Stoelcker B, Echtenacher B, Weich HA, Sztajer H, Hcklin DJ, Mannel DN (2000) VEGF\/Flk-1 interaction, a requirement for malignant ascites recurrence. J Interferon Cytokine Res 20:511\u2013517","journal-title":"J Interferon Cytokine Res"},{"key":"992_CR14","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0002-9440(10)65669-6","volume":"153","author":"S Mesiano","year":"1998","unstructured":"Mesiano S, Ferrara N, Jaffe RB (1998) Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153:1249\u20131256","journal-title":"Am J Pathol"},{"key":"992_CR15","first-page":"445","volume":"20","author":"A Yukita","year":"2000","unstructured":"Yukita A, Asano M, Okamoto T, Mizutani S, Suzuki H (2000) Suppression of ascites formation and re-accumulation associated with human ovarian cancer by anti-VPF monoclonal antibody invivo. Anticancer Res 20:445\u2013454","journal-title":"Anticancer Res"},{"key":"992_CR16","first-page":"E73","volume":"93","author":"C Brahimi-Horn","year":"2006","unstructured":"Brahimi-Horn C, Pouyssegur J (2006) The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer 93:E73\u2013E80","journal-title":"Bull Cancer"},{"key":"992_CR17","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/cncr.10774","volume":"95","author":"E Sivridis","year":"2002","unstructured":"Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI (2002) Association of hypoxia-inducible factors 1\u03b1 and 2\u03b1 with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95:1055\u20131063","journal-title":"Cancer"},{"issue":"7","key":"992_CR18","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2174\/187152008785914798","volume":"8","author":"JP Cosse","year":"2008","unstructured":"Cosse JP, Michiels C (2008) Tumor hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 8(7):790\u2013797","journal-title":"Anticancer Agents Med Chem"},{"key":"992_CR19","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/82146","volume":"6","author":"AL Kung","year":"2000","unstructured":"Kung AL, Wang S, Klco JM, Kalein WG, Livingston DM (2000) Supression of tumor growth through disruption of hypoxia inducible transcription. Nat Med 6:1335\u20131340","journal-title":"Nat Med"},{"key":"992_CR20","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00109-007-0281-3","volume":"85","author":"C Brahimi-Horn","year":"2007","unstructured":"Brahimi-Horn C, Chiche J, Pouyssegur J (2007) Hypoxia and cancer. J Mol Med 85:1301\u20131307","journal-title":"J Mol Med"},{"key":"992_CR21","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1128\/MCB.13.8.5020","volume":"13","author":"V Gekeler","year":"1993","unstructured":"Gekeler V, Epple Kleyman J, Probst H (1993) Selective synchronous activation of early S-phase replicons of Ehrlic ascites cells. Mol Cell Biol 13:5020\u20135033","journal-title":"Mol Cell Biol"},{"key":"992_CR22","first-page":"2053","volume":"48","author":"H Probst","year":"1998","unstructured":"Probst H, Schiffer H, Gekeler V, Kienzle-Pfeilsticker H, Stropp U, Stotzer KE, Frenzel-Stotzer I (1998) Oxygen dependent regulation of DNA synthesis and growth of Ehrlich ascites tumor cells in vitro and in vivo. Cancer Res 48:2053\u20132060","journal-title":"Cancer Res"},{"key":"992_CR23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/cncr.11873","volume":"100","author":"P Buchler","year":"2004","unstructured":"Buchler P, Reber HA, Buchler MW, Friess H, Lavey HRS, Hines OJ (2004) Antiangiogenic activity of genistien in pancreatic carcinoma cell is mediated by the inhibition of Hypoxia inducible factor-1 and the down regulation of VEGF gene expression. Cancer 100:201\u2013210","journal-title":"Cancer"},{"key":"992_CR24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/379088a0","volume":"379","author":"TG Graeber","year":"1996","unstructured":"Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ (1996) Hypoxic mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379:88\u201391","journal-title":"Nature"},{"key":"992_CR25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nm0297-177","volume":"3","author":"G Helmlinger","year":"1997","unstructured":"Helmlinger G, Yuan F, Dellian M, Jain RK (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurement reveal a lack of correlation. Nat Med 3:177\u2013182","journal-title":"Nat Med"},{"key":"992_CR26","first-page":"713","volume":"25","author":"M Inoue","year":"2004","unstructured":"Inoue M, Mukai M, Hamanaka Y, Tatsuta M, Hiraoka M, Kondoh S (2004) Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites. Int J Oncol 25:713\u2013720","journal-title":"Int J Oncol"},{"key":"992_CR27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-3-540-37696-5_19","volume":"174","author":"DM Noonan","year":"2007","unstructured":"Noonan DM, Benelli R, Albini A (2007) Angiogenesis and cancer prevention: a vision. Recent Results Cancer Res 174:219\u2013224","journal-title":"Recent Results Cancer Res"},{"key":"992_CR28","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1016\/j.bmc.2005.03.012","volume":"13","author":"MTH Khan","year":"2005","unstructured":"Khan MTH, Choudhari MI, Khan KM, Rani M, Atta-ur-Rahman (2005) Structure-activity relationships of tyrosinase inhibitory combinatorial library of 2,5-disubstituted-1,3,4-oxadiazole analogues. Bioorg Med Chem 13:3385\u20133395","journal-title":"Bioorg Med Chem"},{"key":"992_CR29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0223-5234(00)00154-9","volume":"35","author":"BS Holla","year":"2000","unstructured":"Holla BS, Gonsalves R, Shenoy S (2000) Synthesis and antibacterial studies of a new series of 1,2-bis(1,3,4-oxadiazole-2-yl)ethanes and 1,2-bis(4-amino-1,2,4-triazol-3-yl)ethanes. Eur J Med Chem 35:267\u2013271","journal-title":"Eur J Med Chem"},{"key":"992_CR30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0014-827X(02)01245-4","volume":"57","author":"G Sahin","year":"2002","unstructured":"Sahin G, Palaska E, MelikeEkizoglu M, Ozalp M (2002) Synthesis and antimicrobial activity of some 1, 3, 4-oxadiazole derivatives. II Farmaco 57:539\u2013545","journal-title":"II Farmaco"},{"key":"992_CR31","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1016\/j.bmc.2005.05.011","volume":"13","author":"F Macaev","year":"2005","unstructured":"Macaev F, Rusu G, Pogrebnoi S, Gudima A, Stingaci E, Vlad L, Shvets N, Kandemirli F, Dimoglo A, Reynolds R (2005) Synthesis of novel 5-aryl-2-thiol-1,3,4-oxadiazoles and the study of their structure-anti-mycobacterial activities. Bioorg Med Chem 13:4842\u20134850","journal-title":"Bioorg Med Chem"},{"key":"992_CR32","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1021\/jf0201677","volume":"50","author":"XJ Zou","year":"2002","unstructured":"Zou XJ, Lai LH, Jin GY, Zhang ZX (2002) Synthesis of biological activity of 1,3,4-oxadiazole-substituted pyridazinone. J Agric Food Chem 50:3757\u20133760","journal-title":"J Agric Food Chem"},{"key":"992_CR33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0014-827X(01)01176-4","volume":"57","author":"E Palaska","year":"2002","unstructured":"Palaska E, Sahin G, Kelicen P, Durlu NT, Altinok G (2002) Synthesis and antimicrobial activity of some 1,3,4-oxadiazole derivatives. Farmaco 57:101\u2013107","journal-title":"Farmaco"},{"key":"992_CR34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ejmech.2004.02.008","volume":"39","author":"M Amir","year":"2004","unstructured":"Amir M, Shikha K (2004) Synthesis and anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation activities of some new 2-[(2,6-dichloroanilino) phenyl]acetic acid derivatives. Eur J Med Chem 39:535\u2013545","journal-title":"Eur J Med Chem"},{"key":"992_CR35","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.bmcl.2005.02.014","volume":"15","author":"A Zarghi","year":"2005","unstructured":"Zarghi A, Sayyed A, Tabatabai M, Faizi A, Ahadian P, Navabi V, Zanganeh A, Shafiee A (2005) Synthesis and anticonvulsant activity of new 2-substituted-5-(2-benzyloxyphenyl)-1,3,4-oxadiazoles. Bioorg Med Chem Lett 15:1863\u20131865","journal-title":"Bioorg Med Chem Lett"},{"key":"992_CR36","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0022-1139(03)00168-4","volume":"123","author":"X Zheng","year":"2003","unstructured":"Zheng X, Li Z, Wang Y, Chen W, Huang O, Liu C, Song C (2003) Synthesis and insecticidal activities of novel 2,5-disubstituted 1,3,4-oxadiazoles. J Fluor Chem 123:163\u2013169","journal-title":"J Fluor Chem"},{"key":"992_CR37","unstructured":"Meyer HR (1976) Chem Abstr 85 125807 [Swiss Patent (1976) 577, 536]"},{"key":"992_CR38","unstructured":"Hill J (1994) In: Katritzky AR (ed) Comprehensive heterocyclic chemistry. Pergamon Press, Oxford 427(4)"},{"key":"992_CR39","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ejmech.2006.03.002","volume":"41","author":"SL Goankar","year":"2006","unstructured":"Goankar SL, Rai KML, Prabhuswamy B (2006) Synthesis and antimicrobial studies of a new series of 2-[4-[2-(5-ethylpyridin-2-yl) ethoxy] phenyl]-5-substituted-1,3,4-oxadiazoles. Eur J Med Chem 41:841\u2013846","journal-title":"Eur J Med Chem"},{"key":"992_CR40","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1142\/S0192415X0200048X","volume":"30","author":"JJ Je","year":"2002","unstructured":"Je JJ, Shin HT, Chung SH, Lee JS, Kim SS, Shin HD, Jang MH, Kim YJ, Chung JH, Kim EH, Kim CJ (2002) Protective effects of Wuyaoshunqisan against H2O2-induced apoptosis on hippocampal cell line HiB5. Am J Chin Med 30:561\u2013570","journal-title":"Am J Chin Med"},{"key":"992_CR41","first-page":"363","volume-title":"Functional epithelial cells in culture","author":"M Neutra","year":"1989","unstructured":"Neutra M, Louvard D (1989) Functional epithelial cells in culture. Alan R Liss Inc., New York, pp 363\u2013368"},{"key":"992_CR42","doi-asserted-by":"crossref","unstructured":"Giridharan P, Somasundaram ST, Perumal K, Vishwakarma NP, Velmurugan R (2002) Novel substituted methylenedioxylignan suppresses proliferation of cancer cells by inhibiting telomerase and activation of c-myc and caspases leading to apoptosis. Br J Cancer 98\u2013105","DOI":"10.1038\/sj.bjc.6600422"},{"key":"992_CR43","first-page":"273","volume":"57","author":"B Mahadesh","year":"2005","unstructured":"Mahadesh B, Salimath BP (2005) Mechanism of inhibition of ascites tumor growth in mice by curcumin is mediated by NF-kB and caspase activated DNase. Mol Cell Biochem 57:273\u2013278","journal-title":"Mol Cell Biochem"},{"key":"992_CR44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/A:1021647726366","volume":"243","author":"AE Gururaj","year":"2003","unstructured":"Gururaj AE, Belakavadi M, Salimath BP (2003) Antiangiogenic effects of butyric acid involves inhibition of VEGF\/KDR gene expression and endothelial cell proliferation. Mol Cell Biochem 243:107\u2013112","journal-title":"Mol Cell Biochem"},{"key":"992_CR45","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/0076-6879(91)98044-7","volume":"198","author":"P Polverini","year":"1991","unstructured":"Polverini P, Bouck N, Raztinejad F (1991) Assay and Purification of naturally occurring inhibitor of angiogenesis. Methods Enzymol 198:440\u2013450","journal-title":"Methods Enzymol"},{"key":"992_CR46","first-page":"132","volume-title":"Cancer medicine","author":"J Folkman","year":"2000","unstructured":"Folkman J (2000) Tumor angiogenesis. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Pollock RE, Weichselbanm RR (eds) Cancer medicine, 5th edn. Decker Inc, Canada, BC, pp 132\u2013152","edition":"5"},{"key":"992_CR47","first-page":"517","volume-title":"Harrison\u2019s textbook of internal medicine 15th Ed","author":"J Folkman","year":"2001","unstructured":"Folkman J (2001) Angiogenesis. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (eds) Harrison\u2019s textbook of internal medicine 15th Ed. McGraw-Hill, New York, pp 517\u2013530"},{"key":"992_CR48","first-page":"2652","volume":"58","author":"JC Luo","year":"1998","unstructured":"Luo JC, Yamaguchi S, Shinkai A, Shitara K, Shibuya M (1998) Significant expression of vascular endothelial growth factor\/vascular permeability factor in mouse ascites tumors. Cancer Res 58:2652\u20132660","journal-title":"Cancer Res"},{"key":"992_CR49","first-page":"360","volume":"55","author":"JA Nagy","year":"1995","unstructured":"Nagy JA, Morgan ES, Herzberg KT, Meyers MS, Yeo KT, Sioussat TM (1995) Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermiability, and ascites fluid accumulation. Cancer Res 55:360\u2013368","journal-title":"Cancer Res"},{"issue":"1","key":"992_CR50","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00441-008-0675-8","volume":"335","author":"Y Crawford","year":"2009","unstructured":"Crawford Y, Ferrara N (2009) VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 335(1):261\u2013269","journal-title":"Cell Tissue Res"},{"key":"992_CR51","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10555-007-9059-x","volume":"26","author":"G Melillo","year":"2007","unstructured":"Melillo G (2007) Targeting hypoxia cell signalling for cancer therapy. Cancer Metastasis Rev 26:341\u2013352","journal-title":"Cancer Metastasis Rev"},{"key":"992_CR52","first-page":"6449","volume":"49","author":"P Vaupel","year":"1989","unstructured":"Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen, and nutrient supply and metabolic microenvironment of human tumors: a review. Cancer Res 49:6449\u20136465","journal-title":"Cancer Res"},{"key":"992_CR53","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/j.1349-7006.2003.tb01395.x","volume":"94","author":"S Kizaka-Kondoh","year":"2003","unstructured":"Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M (2003) Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 94:1021\u20131028","journal-title":"Cancer Sci"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-0992-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-009-0992-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-0992-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:06:58Z","timestamp":1559038018000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-009-0992-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,16]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["992"],"URL":"https:\/\/doi.org\/10.1007\/s00280-009-0992-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,16]]}}}